Critical Path Institute® (C-Path) is excited to share the latest episode of our Connecting the Dots podcast. In this episode, C-Path CEO Klaus Romero, M.D., M.S., FCP, speaks with Kanwaljit Singh, M.D., MPH, MBA, Executive Director of the International Neonatal Consortium (INC), about the unique challenges and groundbreaking innovations in neonatal drug development.
Neonates—especially premature babies—are not simply smaller versions of older children or adults. Their rapidly changing physiology and complex conditions require specialized approaches. INC brings together pharmaceutical companies, researchers, clinicians, parents, and global regulators to accelerate solutions for these most vulnerable patients.
Listeners will learn about:
- The creation of the Neonatal Adverse Event Severity Scale (NAESS) and the next-generation NAESS 2.0 digital tool.
- How INC built one of the world’s largest neonatal databases with over 380,000 patient records across multiple countries.
- How data integration supports disease progression models, lab reference standards, and new approaches to conditions like bronchopulmonary dysplasia.
- Ongoing efforts to validate biomarkers for neonatal brain injury to accelerate clinical trials.
Together, we’re connecting science, data, and collaboration to transform the future of pediatric and neonatal medicine. Listen now!
